Development of analytical method and validation for Nadolol in pure and pharmaceutical formulations using UV-spectrophotometry and spectrofluorimetry using Hydrochloric acid

Anton Smith A, Akanksha ., Arun R


Objective: Development of analytical methods is in need for the estimation of drugs in pure and different pharmaceutical formulations. A simple, sensitive, rapid, accurate, precise and economic Spectrophotometric and Spectrofluorimetric method were developed and validated for Nadolol in pure and Pharmaceutical formulations. Methods: The wave length (λmax) used for the estimation of Nadolol is 267nm by Spectrophotometry, excitation (λEx)-267nm and emission (λEm)-300nm by Spectrofluorimetry. Results: Linear correlation was obtained between absorbance and concentration of Nadolol in the concentration ranges of 20-60µg/ml with R2 value 0.998 by Spectrophotometry and linear correlation was obtained between intensity of fluorescence and concentration of Nadolol in the concentration ranges of 1-5µg/ml with R2value 0.993 by Spectrofluorimetry in 0.1 N HCl.  The linearity of the calibration curve was validated by the high values of correlation coefficient of regression. LOD and LOQ values for Nadolol were found to be 3.95µg/ml and 11.99µg/ml by Spectrophotometry and 0.90µg/ml and2.74µg/ml by Spectrofluorimetry. Conclusion: Among the two developed methods Spectrofluorimetric method is highly sensitive than the spectrophotometric method. These methods are simple and suitable for the determination of Nadolol in pure and Pharmaceutical preparations.

Full Text:



British Pharmacopoeia, The Department of Health and Social Services and Public Safety, British Pharmacopoeial Commission 2008; 2:1504.

United States Pharmacopeia and National Formulary (USP 30-NF 25). Rockville, MD: United States Pharmacopeia Convention 2007; 2:2694.

Olajire A, Olakunle SI, Olaniyi AA. A new spectrophotometric method for the determination of Nadolol. J Iran Chem Soc 2006; 3(3):277-84.

Vijayalakshmi R, Naga Sri Ramya, Dhanaraju M. Method development for quantification of oxidation complexes of Nadolol and Resveratrol by visible spectrophotometry. Int J Pharm Pharm Sci 2014;7(1):304-07.

Camila T, Pedro LG, Fabio PG, Erika RMKH, Maria IRMS. Quantitative Determination of Nadolol in Tablets by High-Performance Liquid chromatography and UV-Derivative Spectrophotometry. Anal Lett 2008; 41(3):424-36.

Eugene Ivashkiv. Colorimetric determination of Nadolol in Tablets. J Pharm Sci 1978; 67(7): 1024-1025.

Amin AS, Ragab GH, Saleh H. Colorimetric determination of beta blockers in pharmaceutical formulations. J Pharm Biomed Anal 2002; 30(4):1347-53.

Eugene I. Fluorimetric determination of Nadolol in human serum and urine. J Pharm Sci 1977; 66(8):1168-1172.

Perlman S, Szyper M, Kirschbaum JJ. High-performance liquid chromatographic analysis of nadolol and bendroflumethiazide combination tablet formulations. J Pharm Sci 1984; 73(4) :259-61.

Bhupendra R. Patel, Joel JK, Raymond BP. High-pressure liquid chromatography of nadolol and other β-adrenergic blocking drugs. J Pharm Sci 1981; 70(3):336-38.

Chandana, Manepalli. Method development and validation for simultaneous estimation of Nadolol and Bendroflumethiazide in pharmaceutical dosage form by using RP-HPLC method. J Pharm Sci 2012; 4(1):216-227.

Srinivas NR, Shyu WC, Shah VR, Campbell DA, Barbhaiya RH. High-performance liquid chromatographic assay for the quantitation of nadolol in human plasma using fluorescence detection. Biomed Chromatogr 1995; 9(2):75-79.

Magdalena O, Katarzyna D, Waldemar B, Barbara Ć, Maciej S, Grzegorz S, Juliusz, Witold D. Radiodegradation of nadolol in the solid state and identification of its radiolysis products by UHPLC–MS method. Chem Pap 2018; 72(2):349–357.

Alaa A, Salem Ibrahim Wasfi Salama S, Al-Nassib M, Allawy MN, Al-Katheeri. Determination of Some β-Blockers and β2-Agonists in Plasma and Urine Using Liquid Chromatography–tandem Mass Spectrometry and Solid Phase Extraction. J Chromatogr Sci 2017; 55(8):846–856.

International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Validation of Analytical Procedures: Text and Methodology, Q2 (R1), 2005.


  • There are currently no refbacks.